Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Raltegravir and hyper-immune bovine colostrum intensification in ART-treated HIV patients with poor CD4 recovery
ACTRN12609000575235Phase 4Active, not recruiting
- Sponsor
- University of New South Wales
- Start
- Mar 2009
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of raltegravir and IMM-124E in human immunodeficiency virus infection (HIV) (4 arms), sponsored by University of New South Wales. Primary endpoint: Change from baseline in CD4+ T-cell count. Started Mar 2009; status: active, not recruiting.
02
Drugs
raltegravirIMM-124E
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on ACTRN12609000575235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12609000575235.